Saturday, 7 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

United States Business Intelligence Software Market Analysis 2025-2033 by Technology, Deployment, Enterprise, End User, States and Competitive Landscape

View original at globenewswire.com
United States Business Intelligence Software Market Analysis 2025-2033 by Technology, Deployment, Enterprise, End User, States and Competitive Landscape Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The drivers of BI market growth are rising data-driven decision-making, improving analytics, and growing demands for data visualization and reporting tools from companies across industries

    80% confidence
  • Qlik is on a mission to enable today's businesses to turn trust data into something actionable, access it, analyze it and act on it

    80% confidence
  • The U.S. BI software market will demonstrate a Compound Annual Growth Rate of 10.33% during 2025 to 2033

    80% confidence
  • Data security is a major issue in BI software adoption, especially for industries like healthcare, banking, and government dealing with sensitive data

    80% confidence
  • Cloud BI has the potential to lead the U.S. BI market in the future years due to increasing popularity of subscription-based models and superior security protocols

    80% confidence
  • High implementation and maintenance costs remain a challenge in the U.S. BI market, particularly for small and mid-size businesses

    80% confidence
  • The United States Business Intelligence Software Market is expected to grow from US$ 11.35 Billion in 2024 to US$ 27.49 Billion by 2033

    80% confidence
  • More than 80% of companies will move to the cloud as of 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com